César Li-Amenero

César Li-Amenero

Auto-generated profile, based on publicly available information

César Li-Amenero

Hospital Víctor Larco Herrera, Magdalena del Mar, Lima, Peru

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2025 in Pharmacia
Verified
Journal Article
Open access
PDF file
Angel T. AlvaradoAngel T. Alvarado
Angel T. Alvarado
ALBERTO SALAZAR GRANARAALBERTO SALAZAR GRANARA
ALBERTO SALAZAR GRANARA
NVNelson Varela
Nelson Varela
Luis A. QuiñonesLuis A. Quiñones
Luis A. Quiñones
CLCésar Li-Amenero
César Li-Amenero
RPRicardo Pariona-Llanos
Ricardo Pariona-Llanos
The CYP1A1 isoenzyme is responsible for the biotransformation of procarcinogens, such as Benzo(a)pyrene, into reactive metabolites. Meanwhile, GSTM1 facilitates the detoxification of these metabolites by conjugating them with glutathione. The presence of the CYP1A1*2A genetic variant intensifies the production of these reactive metabolites, and the deletion of the GSTM1 gene (GSTM1*0) impairs their detoxification. This enzymatic imbalance leads to the formation of DNA adducts, which are known to contribute to cancer and other diseases. Given the importance of studying these genes within the framework of 4P medicine (predictive, preventive, personalized, and participatory), the primary objective of this study was to investigate the prevalence of GSTM1*0 and CYP1A1*2A in the central Peruvian coastal Population as genetic biomarkers. The study included 131 individual residents of the Peruvian towns of Ica and Lima. The results showed a frequency of 0.47 for GSTM1*0 and an allele frequency of 0.68 for CYP1A1*2A. The genotype frequencies of CYP1A1*2A were 6% *1A/*1A, 53% *1A/*2A, and 41% *2A/*2A. Notably, the population sample is not in the Hardy-Weinberg equilibrium (χ2 = 5.324) for CYP1A1. The reported frequencies of GSTM1*0 and CYP1A1*2A in this study differ from those previously documented for other Latin American and tricontinental populations, potentially reflecting the unique natural evolution and genetic admixture of the Peruvian population. The high prevalence of GSTM1*0 and CYP1A1*2A identified in populations from Ica and Lima suggests a potentially elevated risk of exposure to procarcinogens such as polycyclic aromatic hydrocarbons (PAHs). This finding underscores the need for further research on a larger scale to validate and expand upon these results. Graphical abstract:

1 November 2022 in Journal of Pharmacy & Pharmacognosy Research
Verified
Journal Article
Open access
Angel T. AlvaradoAngel T. Alvarado
Angel T. Alvarado
JCJuan Cotuá
Juan Cotuá
MDMaryori Delgado
Maryori Delgado
AMAlexis Morales
Alexis Morales
Naysha Rojas-VillaNaysha Rojas-Villa
Naysha Rojas-Villa
MPMario Pineda-Pérez
Mario Pineda-Pérez
Context: Therapeutic drug monitoring (TDM) allows personalizing the dose of valproic acid in patients with epilepsy to optimize drug therapy, minimize adverse effects and detect interactions. Aims: To determine valproic acid concentrations in serum samples from people with epilepsy and to analyze its clinical implications. Methods: Cloned donor enzyme immunoassay; descriptive, cross-sectional, non-randomized, convenience recruitment study of 57 voluntary patients with epilepsy (n = 39 male, 68.42%; n = 18 female, 31.58%) aged between 19 and 62 years. After three months of treatment with valproic acid, a single blood sample was collected from each volunteer at a minimal concentration. Results: Serum drug concentrations 51.30-100.10 mg/L (SD 5.94) and level/dose 2.17-5.31 (SD 1.14) were observed. Association was shown between the dose ratio/dose of valproic acid (R2 = 0.8693; p<0.05) and the Mann-Whitney U test (p α = 0.05). Conclusions: Serum valproic acid concentrations are within the therapeutic range, and there is a significant inverse linear correlation between dose ratio/dose, which must be considered to personalize the dose and optimize the pharmacotherapeutic result.

1 May 2025 in Journal of Pharmacy & Pharmacognosy Research
Verified
Journal Article
Open access
Angel T. AlvaradoAngel T. Alvarado
Angel T. Alvarado
MBMario Bolarte-Arteaga
Mario Bolarte-Arteaga
MPMario Pineda-Pérez
Mario Pineda-Pérez
CLCésar Li-Amenero
César Li-Amenero
HCHaydee Chavez
Haydee Chavez
RPRicardo Pariona-Llanos
Ricardo Pariona-Llanos
Context: Cancer is a global health problem with a growing incidence year after year, and it is projected that by 2040, there will be more than 2.4 million cases in Latin America and the Caribbean, being the second cause of death in these countries. The variability of serum levels, efficacy and safety of paclitaxel and docetaxel have been associated with allelic variants of transporter and metabolizing proteins. Aims: To review the most updated and available scientific evidence on allelic variants of CYP3A4*20, CYP3A4*22, CYP2C8*3, and SLCO1B1 as genetic biomarkers to predict peripheral neuropathy induced by paclitaxel and docetaxel. Methods: PRISMA was used, and a standardized search was followed in Medline/PubMed and Google Scholar with the terms: CYP3A4, CYP2C8, SLCO1B1, genetic biomarker of neuropathy and neuropathy due to paclitaxel and docetaxel. Data extraction was performed using Excel, and relevant information on allelic variants was collected as genetic biomarkers to predict peripheral neuropathy induced by paclitaxel and docetaxel. Results: Eight studies indicate an association between the allelic variants of the study with peripheral neuropathy: CYP2C8*3 (HR: 1.93; 95% CI: 1.05-3.55; p=0.006), CYP3A4*22 (p=0.043), CYP3A4*20, CYP3A4*8 and CYP3A4*27 (p=5.9 × 10-5), CYP2C8 and CYP3A4 (p=1.8 × 10-6), SLCO1B1 (HR: 0.67; 95% CI: 0.46-0.97; p=0.02), SLCO1B3 (OR: 9.44), CYP3A4 (OR: 2.259; 95% CI: 1.033-4.941; p=0.038), CYP3A4*22 (RR: 6.92; 95% CI: 0.47-99.8; p=0.0766) and CYP2C8*3/*4 (RR: 1.28; 95% CI: 0.96-1.67; p=0.0898). No pharmacogenetic studies were found in cancer patients in Peruvian populations. Conclusions: Based on the review of the published scientific evidence, it is concluded that the allelic variants CYP3A4*22, CYP3A4*20 and CYP2C8*3 are associated with a modest risk of peripheral neuropathy induced by paclitaxel and docetaxel, while SLCO1B1 has less evidence.

30 June 2021 in Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo
Verified
Journal Article
Open access
MCMilagros Calla-Torres
Milagros Calla-Torres
MHMaría Hurtado-Ruiz
María Hurtado-Ruiz
JGJose Galvez-Olortegui
Jose Galvez-Olortegui
CLCésar Li-Amenero
César Li-Amenero
Letter to the Editor (without abstract) Carta al Editor (sin resumen)

29 December 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JFJavier A. Flores-Cohaila
Javier A. Flores-Cohaila
JHJeff Huarcaya
Jeff Huarcaya
CLCesar Li-Amenero
Cesar Li-Amenero
SSSantiago Stucchi-Portocarrero
Santiago Stucchi-Portocarrero
CSCarlos Alexis Salgado-Valenzuela
Carlos Alexis Salgado-Valenzuela
Cesar Augusto Copaja CorzoCesar Augusto Copaja Corzo
Cesar Augusto Copaja Corzo
To date, no studies have investigated the effect of native language on depressive symptom networks. To address this gap, we examined depression symptom network structure across four major cultural-linguistic groups in Peru (Castellano, Quechua, Aymara, and Amazonian indigenous languages). We conducted a network analysis of PHQ-9 depression symptoms using nationally representative data from 31,276 Peruvian participants. Networks were estimated using ggmModSelect with Spearman correlations. Native language groups were compared using permutation tests to evaluate network differences. Depression networks exhibited distinct architectures across groups, with Castellano showing the highest connectivity (22 active edges), followed by Quechua (20 edges) and Aymara (12 edges, p < 0.019). While worthlessness/guilt-suicidal ideation was the strongest universal pathway (r = 0.377–0.44), groups exhibited distinct centrality patterns: Castellano networks centered on depressed mood, Quechua on fatigue, and Aymara on suicidal ideation. Aymara networks showed absence of anhedonia-depressed mood connections (r = 0.00) and unique psychomotor-suicidal ideation pathways (r = 0.27), which requires further exploration. It is suggested that native language may shape depression architecture, suggesting distinct cultural-linguistic patterns that challenge current depression models.

3 October 2024 in Revista Peruana de Medicina Integrativa
Verified
Journal Article
Open access
TVTania D. Vizquerra-Sifuentes
Tania D. Vizquerra-Sifuentes
MOMaría E. Ojeda-Chávez
María E. Ojeda-Chávez
CLCésar Li-Amenero
César Li-Amenero
JHJuan Huaccho-Rojas
Juan Huaccho-Rojas
El uso de las terapias mente-cuerpo es una buena alternativa no farmacológica para prevenir o abordar la presencia de síntomas mentales en estudiantes de la salud, tomando en cuenta el contexto de la pandemia por COVID-19. El objetivo de este estudio fue determinar la asociación entre síntomas mentales y el uso de terapias mente cuerpo en estudiantes de Medicina Humana (MH) de la Universidad Científica del Sur. Para esto, se realizó un estudio transversal analítico observacional, en 384 estudiantes universitarios de la carrera de Medicina Humana. A través de un cuestionario on line se recogieron variables sociodemográficas y clínicas, donde se incluyó la versión en español de escala de Ansiedad, Depresión y estrés (DASS-21), entre marzo y abril del 2021. Los resultados indican que 28,6% (86 estudiantes) realizó alguna terapia mente-cuerpo, siendo el 70% mujeres. Los síntomas depresivos estuvieron en 68,49%, síntomas de ansiedad con 65,89% y síntomas de estrés con 63,27%. El 26,82% de los estudiantes tuvo COVID-19 y la terapia mente-cuerpo más prevalente fue el yoga. El estudio subraya que el uso de terapias mente cuerpo tiene asociación a la presencia de síntomas mentales y menor asociación con la presencia de COVID 19 y la edad.